I. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 3, 1996, Pages 1306-1312

  Wallace, Thomas L ^a   Bazemore, Scott A ^a   Kornbrust, Douglas J ^b   Cossum, Paul A ^a  

^a Antigenics Inc   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; UNCLASSIFIED DRUG; ZINTEVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE INHIBITOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; HEMODYNAMIC MONITORING; HEMOLYSIS; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TOXICITY TESTING; TRIPLE HELIX; ANIMAL; BLOOD CLOTTING; COMPLEMENT ACTIVATION; DRUG EFFECT; HEMODYNAMICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA; PARTIAL THROMBOPLASTIN TIME;

ANIMALS; ANTI-HIV AGENTS; BLOOD COAGULATION; COMPLEMENT ACTIVATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; MACACA FASCICULARIS; OLIGONUCLEOTIDES; PARTIAL THROMBOPLASTIN TIME;

EID: 0030302478     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. BLACK, L. E., FARRELLY, J. G., CAVAGNARO, J. A., AHN, C. H., DEGORGE, J. J., TAYLOR, A. S., DEFELICE, A. F. AND JORDAN, A.: Regulatory considerations for oligonucleotide drugs: Updated recommendations for pharmacology and toxicology studies. Antisense Res. Dev. 4: 299-301, 1994.
2. CHUBB, J. M. AND HOGAN, M. E.: Human therapeutics based on triple helix technology. Trends in Biotechnology 10: 132-136, 1992.
3. CORNISH, K. G., IVERSEN, P., SMITH, L., ARNESON, M. AND BAYEVER, E.: Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol. Commun. 3: 239-247, 1993.
4. DAVIES, B. AND MORRIS, T.: Physiological parameters in laboratory animals and humans. Pharmaceutical Res. 10: 1093-1095, 1993.
5. GALBRAITH, W. M., HOBSON, W. C., GICLAS, P. C., SCHECHTER, P. J. AND AGRAWAL, S.: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4: 201-206, 1994.
6. GRIFFIN, L. C., TIDMARSH, G. F., BOCK, L. C., TOOLE, J. J. AND LEUNG, L. L. K.: In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81: 3271-3276, 1993.
7. HEIERLI, C., MARKERT, M., LAMBERT, P. H., KUWAHARA, T. AND WAUTERS, J. P.: On the mechanisms of haemodialysis-induced neutropenia: A study with five new and re-used membranes. Nephrol. Dial. Transplant 3: 773-783, 1988.
8. HENRY, S. P., LARKIN, R., NOVOTNY, W. F. AND KORNBRUST, D. J.: Effects of Isis 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters. Pharmaceutical Res. 11: S353, 1994.
9. JACOBS, JR., A. A., WARD, R. A., WELLHAUSEN, S. R., AND MCLEISH, K. R.: Polymorphonuclear leukocyte function during hemodialysis: Relationship to complement activation. Nephron 52: 119-124, 1989.
10. LEE, W. A., FISHBACK, J. A., SHAW, J.-P., BOCK, L. C., GRIFFIN, L. C. AND CUNDY, K. C.: A novel oligodeoxynucleotide inhibitor of thrombin. II. Pharmacokinetics in the cynomolgus monkey. Pharmaceutical Res. 12: 1943-1947, 1995.
11. MARSHALL, W. S. AND CARUTHERS, M. H.: Phosphorodithioate DNA as a potential therapeutic drug. Science (Wash. DC) 259: 1564-1570, 1993.
12. OJWANG, J., BUCKHEIT, R. W., POMMIER, Y., MAZUMDER, A., DE VREESE, K., ESTE, J. A., REYMAN, D., PALLANSCH, L. A., LACKMAN-SMITH, C., WALLACE, T. L., DE CLERQ, E., MCGRATH, M. S. AND RANDO, R. F.: AR177, an oligonucleotide stabilized by an intramolecular guanosine-octet, is a potent inhibitor of laboratory strains and clinical isolates of the human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39: 2426-2435, 1995.
13. RANDO, R. F., OJWANG, J., ELBAGGARI, A., REYES, G. R., TINDER, R., MCGRATH, M. S. AND HOGAN, M. E.: Suppression of human immunodeficiency virus activity in vitro by oligonucleotides which form intramolecular tetrads. J. Biol. Chem. 270: 1754-1760, 1995.
14. ROWLAND, M. AND TOZER, T. N.: Clinical Pharmacokinetics. Concepts and Applications, 3rd ed. Williams and Wilkins, Baltimore, 1995.
15. STEIN, C. A. AND CHENG, Y.-C.: Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science (Wash. DC) 261: 1004-1012, 1993.
16. STULL, R. A. AND SZOKA JR., F. C.: Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects. Pharm. Res. 12: 465-483, 1995.
17. WALLACE, T. L., BAZEMORE, S. A., KORNBRUST, D. AND COSSUM, P. A.: II. Repeatdose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys. J. Pharmacol. Exp. Ther. 278:1313-1319, 1996.